Evidence map›Paper›PMID 39112775›Full record

ArticlePharmaceutical research2024

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization.

Mohammad A M Momin, Dale Farkas, Michael Hindle, Felicia Hall, Robert M DiBlasi, Worth Longest

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Mohammad A M Momin *Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.
Dale Farkas *Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, 401 West Main Street, P.O. Box 843015, Richmond, Virginia, 23284-3015, USA.
Michael HindleDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.
Felicia HallDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.
Robert M DiBlasiCenter for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.
Worth LongestDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA. pwlongest@vcu.edu.ORCID http://orcid.org/0000-0003-4939-5691

Funding

High Efficiency Delivery of Surfactant Aerosols to Infants without IntubationR01HL139673 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HINDLE, MICHAEL, LONGEST, P. WORTH · 2018 to 2021
$2.8M
Bill and Melinda Gates Foundation INV-055026Bill and Melinda Gates Foundation INV-058340NHLBI NIH HHS HL139673NHLBI NIH HHS R01 HL139673
6 · The paper itself

Abstract

purposeImproving the deep lung delivery of aerosol surfactant therapy (AST) with a dry powder formulation may enable significant reductions in dose while providing improved efficacy. The objective of Part I of this two-part study was to present the development of a new dry powder aerosol synthetic lung surfactant (SLS) product and to characterize performance based on aerosol formation and realistic in vitro airway testing leading to aerosol delivery recommendations for subsequent in vivo animal model experiments.

methodsA new micrometer-sized SLS excipient enhanced growth (EEG) dry powder formulation was produced via spray drying and aerosolized using a positive-pressure air-jet dry powder inhaler (DPI) intended for aerosol delivery directly to intubated infants with respiratory distress syndrome (RDS) or infant-size test animals.

resultsThe best-case design (D2) of the air-jet DPI was capable of high emitted dose (> 80% of loaded) and formed a < 2 µm mass median aerodynamic diameter (MMAD) aerosol, but was limited to ≤ 20 mg mass loadings. Testing with a realistic in vitro rabbit model indicated that over half of the loaded dose could penetrate into the lower lung regions. Using the characterization data, a dose delivery protocol was designed in which a 60 mg total loaded dose would be administered and deliver an approximate lung dose of 14.7-17.7 mg phospholipids/kg with a total aerosol delivery period < 5 min.

conclusionsA high-efficiency aerosol SLS product was designed and tested that may enable an order of magnitude reduction in administered phospholipid dose, and provide rapid aerosol administration to infants with RDS.

Indexed as

AerosolsDry Powder InhalersLungParticle SizePowdersPulmonary SurfactantsRespiratory Distress Syndrome, NewbornAdministration, InhalationAnimalsExcipientsHumansInfant, NewbornRabbitsAerosolsExcipientsPowdersPulmonary Surfactantsinfant aerosol therapyrespiratory distress syndromesurfactant aerosolsurfactant replacement therapysynthetic lung surfactant

Identifiers

PMID39112775
PMCPMC11362531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.